Abstract 2749
Background
With the expanding use of CPI in different types of cancer, we have been challenged with the lack of safety and efficacy data of CPI post allogeneic stem cell therapy (SCT).
Methods
We systematically reviewed our institutional databases through March 2018 and identified patients (pts) who received CPI for treatment of cancer after allogeneic SCT. In addition, we systematically reviewed the literature through August 2018 to identify studies reporting use of CPIs post-allogeneic SCT. We evaluated the prevalence of graft vs host disease (GVHD), immune-related adverse events (irAEs), tumor response, and mortality after CPI.
Results
A total of 38 pts were identified (10 from institutional databases & 28 from literature). The median age was 37.5 years (range 10–68 yrs). The most commonly used CPI was anti-PD1 84 %. Cancer types included hematologic malignancies (n = 36); primarily Hodgkin lymphoma in 58%, and solid tumors (n = 2). Median time to CPI initiation post SCT was 1.6 years (range 0.92–32 yrs). More than half of pts (59 %) were maintained on immunosuppressive agents: brentuximab vedotin, cyclophosphamide, and low dose prednisone at CPI initiation. GVHD occurred in 34.2 % (n = 13); nine were specified having acute GVHD (82%). The median time from initiation of CPI to GVHD was 14 days (range 5-21 days). In most pts, GVH was treated with steroids. Two thirds of pts achieved complete or partial tumor remission (ORR 66%), while 28% had disease progression. In pts who developed GVHD the ORR was 91.2%. Interestingly, of the 25 pts who were reported to have no GVHD, 10 had irAEs. There were total of 34% of death (n = 13), including 5% only (n = 2) were attributed to GVHD, while the remaining were secondary to either progression of disease, CPI irAE’s (Pneumonitis, Myocarditis), and other causes.
Conclusions
The use of CPI post-SCT has a significant anti-tumor response, but it was associated with an increased risk of acute GVHD. Prospective studies in this population (CPI post-SCT) with longitudinal on treatment biopsies are needed to understand the differences between allo-immunity, tumor immunity and auto-immunity (irAE).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Adi Diab.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2494 - CAR-T Nursing Education at a UK Specialist Cancer Hospital
Presenter: Rose Ellard
Session: Poster Display session 3
Resources:
Abstract
2438 - Professional Quality of Life, Perceived Stress and Psychological Resistance Levels of Oncology-Hematology Nurses and the Factors Affecting
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
3541 - Representation of cancer survivors’ preferences in policies for supportive care: Implications for oncology nursing
Presenter: Samantha Mayo
Session: Poster Display session 3
Resources:
Abstract
5093 - Vaginal moisturizing post PDR-Pulse Dose Rate Brachytherapy.
Presenter: Pilar Fernández
Session: Poster Display session 3
Resources:
Abstract
1066 - The stomized, chemo and radiotreated patient vs untreated patient: complications and comparison with data literature
Presenter: Cristoforo Ferrero
Session: Poster Display session 3
Resources:
Abstract
1724 - Evaluating the role of clinical nurse specialist
Presenter: Anita Zeneli
Session: Poster Display session 3
Resources:
Abstract
3753 - Role of the Advanced Practice Nurse (APN) in a Functional Unit for Lung cancer at the Catalan Institute of Oncology
Presenter: Isabel Brao
Session: Poster Display session 3
Resources:
Abstract
2676 - A bottom-up approach for prioritising the scientific activities of the Italian Association of Cancer Nurses (AIIAO): rationale and topic identification
Presenter: Valentina Biagioli
Session: Poster Display session 3
Resources:
Abstract
575 - Investigating quality of care for people with cancer and dementia
Presenter: Naomi Farrington
Session: Poster Display session 3
Resources:
Abstract
5578 - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France
Presenter: Kelly Dufraing
Session: Poster Display session 3
Resources:
Abstract